Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|November 2, 2018
- Pharmaceutical Technology-11-02-2018
- Volume 42
- Issue 11
Bioimaging Molecular Probes
Stream Bio’s Conjugated Polymer Nanoparticle products are a new generation of novel molecular bioimaging probes for diagnostic and therapeutic applications.
Stream Bio’s Conjugated Polymer Nanoparticle (CPN) products are a new generation of novel molecular bioimaging probes for diagnostic and therapeutic applications. The highly fluorescent, non- toxic nanoparticles come in emission wavelengths 475, 510, 550, and 680 nm, covering colors blue, green, yellow, and red.
The products can be used in molecular imaging and R&D applications, including flow cytometry, enzyme-linked immunosorbent assay, fluorescent in situ hybridization, western blotting fluorescence resonance energy transfer, intensity-hue-saturation, and lateral flow assays.
The CPNs provide significant photostability and sensitivity (brightness) with highly specific targeting and magnetic cell-purification capability, while remaining compliant with existing lab protocols, the company reports.
Articles in this issue
almost 8 years ago
Guidelines on Integral Drug-Device Combinationsalmost 8 years ago
Detachable AODD Pumpalmost 8 years ago
Advanced Paddle Blender for Labsalmost 8 years ago
Custom Multi-Shaft Mixeralmost 8 years ago
User Requirements Specifications–How Difficult Can It Be?almost 8 years ago
Single-Use Bioprocessing Equipment Trends and Adoption by CMOsalmost 8 years ago
Innovations in Prefilled Syringes for Biologic Drugsalmost 8 years ago
Media Requirements for Different Cell SourcesRelated to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
Pharma Leaders Weigh in On AI's Measurable Results In 2026
3
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5